REVIVE-PEEP trial research protocol

The REVIVE-PEEP trial is a multicenter, triple-blind, randomized controlled study designed to determine whether applying 8 cm H2O of positive end-expiratory pressure (PEEP) during manual ventilation for out-of-hospital cardiac arrest improves neurological outcomes at hospital discharge compared to zero end-expiratory pressure.

The Gist

🚑 The Big Picture: A Race Against Time

Imagine a person has collapsed outside their home. Their heart has stopped. The ambulance arrives, and the paramedics start doing CPR (chest compressions) and breathing for the patient.

The goal is simple: Keep the brain and heart alive until the heart starts beating on its own again.

For decades, doctors have argued about how to breathe for these patients. Specifically, they are debating whether to add a little bit of "back-pressure" to the lungs when the patient breathes out. This is called PEEP (Positive End-Expiratory Pressure).

• The Old Way (ZEEP): Let the lungs deflate completely, like a balloon with no air left in it.
• The New Idea (PEEP): Keep the lungs slightly inflated, like a balloon that is never fully deflated, so it's easier to blow up again.

The REVIVE-PEEP study is a massive experiment to find out which method saves more brains and lives.

---

🎈 The Core Problem: The "Sticky" Lungs

When someone is in cardiac arrest, their lungs often collapse a bit (like a wet sponge that has been squeezed dry). This is called atelectasis.

• The Analogy: Imagine trying to blow up a very sticky, deflated balloon. If you let it go completely flat every time, it takes a lot of effort to get it open again. But if you keep a tiny bit of air in it so it stays slightly puffed up, it's much easier to fill it with fresh oxygen.
• The Theory: By using a special valve that keeps a little pressure in the lungs (8 cm H₂O), we might keep the "sticky" airways open, allowing more oxygen to get into the blood and reach the brain.

But there's a catch: Some doctors worry that this extra pressure might squeeze the heart too hard, making it harder for blood to get back to the heart to be pumped out again. It's a delicate balance.

---

🧪 The Experiment: The "Magic Valve"

This study is a Randomized Controlled Trial, which is the gold standard of medical research. Here is how it works:

1. The Setup: Paramedics in the Netherlands have special "Resuscitation Kits" in their ambulances.
2. The Mystery: Inside these kits are two types of valves that look exactly the same.
   • Valve A (The Hero): Adds the 8 cm pressure (PEEP).
   • Valve B (The Control): Adds zero pressure (ZEEP).
3. The Shuffle: The kits are pre-mixed randomly. When a paramedic grabs a kit for an emergency, they have no idea which valve they are using. It's like opening a box of chocolates where you don't know if you're getting the caramel or the chocolate.
4. The Blindfold: The patient is unconscious, the paramedics don't know which valve they have, and the doctors analyzing the results later won't know either. This ensures the results are 100% fair.

The Goal: They want to see if the group with the "Hero" valve has more people waking up with their brains intact compared to the group with the "Control" valve.

---

📊 The Rules of the Game

• Who is in the study? Adults who have a cardiac arrest outside the hospital.
• Who is NOT in the study? People whose hearts stopped because of a car crash (trauma) or drowning. These situations are too different to compare fairly.
• How many people? They need about 2,400 patients who get a breathing tube or a special airway mask to get a clear answer.
• The "Principal Stratum": This is a fancy way of saying, "We only count the results for the people where the breathing tube actually worked." If the paramedics couldn't get the airway open, that patient is excluded from the final math, just like you wouldn't judge a race if the runner never left the starting line.

---

⚖️ The Risks vs. Rewards

The Risks:

• Could the extra pressure hurt the heart? (Unlikely at this low level).
• Could it make it harder to shock the heart back to rhythm? (Modern machines adjust automatically, so probably not).
• Could it cause a collapsed lung? (A small risk, but manageable).

The Rewards:

• If this works, it's a huge win. It's cheap, easy to use, and requires no new drugs.
• If it saves even a few more people from brain damage, it could change how ambulances work worldwide.

---

🏁 The Bottom Line

Right now, we don't know for sure if adding that little bit of pressure helps or hurts. It's a bit like guessing whether a car runs better with a slightly tighter tire pressure or a slightly looser one.

The REVIVE-PEEP study is the ultimate test drive. By testing thousands of real-life emergencies with a fair, blind comparison, they hope to give doctors a definitive answer: "Yes, keep the lungs slightly puffed up," or "No, let them deflate."

If the answer is "Yes," it could mean thousands more people surviving cardiac arrest with their minds intact, simply because a paramedic used a slightly different valve.

Technical Summary

Based on the provided research protocol, here is a detailed technical summary of the REVIVE-PEEP study.

1. Problem Statement and Rationale

• Clinical Burden: Out-of-hospital cardiac arrest (OHCA) remains a major global health burden with stagnant survival rates despite improvements in basic resuscitation. A significant barrier to successful resuscitation is atelectasis (alveolar collapse) during CPR, which impairs gas exchange, leads to hypoxemia, and reduces the likelihood of Return of Spontaneous Circulation (ROSC) and favorable neurological outcomes.
• The Knowledge Gap: While Positive End-Expiratory Pressure (PEEP) is standard in critical care to prevent atelectasis, its use during CPR is inconsistent and controversial.
  • Historical Concern: Theoretical fears that PEEP increases intrathoracic pressure, reduces venous return, lowers cardiac output, and impairs defibrillation.
  • Emerging Evidence: Preclinical and observational data suggest that moderate PEEP (specifically around 8 cm H₂O) improves oxygenation and alveolar recruitment without detrimental hemodynamic effects, potentially optimizing the balance between gas exchange and cardiac output.
• Current Practice: Guidelines lack clear recommendations, leading to wide variability in practice (Zero End-Expiratory Pressure [ZEEP] vs. PEEP) across different regions.

2. Methodology

The REVIVE-PEEP study is designed as an investigator-initiated, pragmatic, registry-based, multicenter, parallel-group, triple-blind, randomized controlled superiority trial.

• Study Setting: Conducted within the ARREST registry (AmsteRdam REsuscitation STudies) covering ambulance services in North-Holland and Flevoland, Netherlands.
• Study Population:
  • Target: Adult patients (≥18 years) with OHCA.
  • Principal Stratum: Patients who undergo advanced airway management (placement of a Supraglottic Airway Device [SAD] or Endotracheal Tube [ETT]) and receive manual positive-pressure ventilation.
  • Exclusions: Traumatic cardiac arrest, drowning, and cases where ventilation is initiated by non-participating services or via mechanical ventilation immediately.
• Intervention:
  • Experimental Group: Ventilation via a standard bag-valve-mask (BVM) system equipped with a PEEP valve delivering 8 cm H₂O.
  • Control Group: Ventilation via an identical-looking sham valve delivering 0 cm H₂O (ZEEP).
  • Device: Custom-modified Ambu SPUR II resuscitator bags with pre-randomized, blinded valves (1:1 ratio).
• Randomization & Blinding:
  • Pre-randomization: Kits are pre-assembled and randomized in blocks of 12 before deployment.
  • Triple-Blind: The patient, ambulance personnel, and researchers (including outcome assessors) are blinded. The valves are identical in appearance (yellow color coding distinguishes them from standard commercial valves but not from each other).
  • Allocation Concealment: Ambulance crews randomly select a kit from their stock; the specific valve type is unknown until the kit is opened.
• Primary Endpoint:
  • Neurological outcome at hospital discharge measured by the Utility-weighted Modified Rankin Scale (UW-mRS).
  • Rationale: This metric captures the full spectrum of neurological function and quality of life, weighting outcomes (0–6) based on patient preferences, rather than using a simple binary "favorable/unfavorable" cutoff.
• Secondary Endpoints:
  • ROSC, 30-day survival, dichotomized favorable neurological survival (mRS 0–3), quality of life (EQ-5D-5L) at 6 months.
  • Safety: Incidence of clinically significant pneumothorax.
  • Mechanistic: Pulmonary mechanics, airway opening index, thoracic impedance, and intra-arrest blood gases.
• Sample Size:
  • Target: 2,400 patients in the principal stratum (those with advanced airways).
  • Total Enrollment: ~3,200 patients (accounting for a ~25% exclusion rate due to ROSC before airway placement).
  • Power: Designed to detect a 4% absolute reduction in mortality (minimally clinically important difference) with 81–91% power.
• Ethical Considerations:
  • Deferred Consent: Due to the emergency nature of OHCA and patient incapacity, consent is obtained post-resuscitation from survivors or legal representatives.
  • Anonymized Data: Neurological outcomes are collected via hospital records. To prevent bias from missing data (common in deferred consent), the protocol requests approval to include anonymized neurological data for all patients, even if consent is later withdrawn.

3. Key Contributions

• First Large-Scale RCT on PEEP in CPR: Unlike previous small pilot studies or observational data, this is a powered, randomized controlled trial specifically designed to determine the efficacy of PEEP in OHCA.
• Pragmatic Design: By embedding the study in routine EMS workflows (using existing registries and standard equipment), the results will have high external validity and immediate applicability to real-world settings.
• Patient-Centered Primary Outcome: The use of UW-mRS instead of a simple dichotomized survival metric addresses the limitation of previous trials (like PARAMEDIC-2) where survival increased but neurological quality of life did not.
• Principal Stratum Analysis: The statistical approach isolates the effect of the intervention specifically in patients where the intervention is physiologically feasible (those with advanced airways), ensuring a precise estimation of the treatment effect.

4. Results

• Status: This document is a Research Protocol (Version 2.1, dated February 2026).
• Outcome: No clinical results are available yet. The study is planned to run for 2.5 years with 6 interim analyses. The document outlines the hypotheses, statistical plans, and safety monitoring procedures but does not report findings.

5. Significance

• Potential to Change Guidelines: If the study demonstrates that 8 cm H₂O PEEP improves neurological survival without increasing adverse events (like pneumothorax or hemodynamic collapse), it could fundamentally alter international CPR guidelines (e.g., ILCOR, ERC) regarding ventilation strategies.
• Cost-Effective Intervention: PEEP valves are low-cost, widely available, and easy to implement. A positive result would offer a scalable, resource-efficient method to improve OHCA outcomes globally.
• Safety Profile: The study rigorously addresses historical concerns regarding hemodynamic compromise and defibrillation efficacy. If safety is confirmed, it resolves long-standing clinical uncertainty.
• Methodological Benchmark: The use of deferred consent, registry-based recruitment, and utility-weighted outcomes sets a high standard for future emergency resuscitation research.

Conclusion: The REVIVE-PEEP study represents a critical step in resolving the debate over ventilation strategies during cardiac arrest. By testing a simple, low-cost intervention against a sham control in a rigorous, blinded, and pragmatic setting, it aims to provide definitive evidence on whether optimizing PEEP can save lives and, more importantly, save brains.